Mersa IV 500/Mersa IV 1000 Adverse Reactions

Neuropsychological system: Because shock and anaphylactoid symptom may rarely occur, patients should be monitored closely. If any adverse reaction is observed, administration should be discontinued and appropriate measure should be taken.
Digestive system: Loose feces, diarrhea, nausea, vomiting and abdominal pain may rarely occur.
Blood system: Oligocythemia, leukopenia, thrombocytopenia and eosinophilia may rarely occur.
Reversible neutropenia has been reported and neutropenia appears to be promptly reversible when this drug is discontinued. Although a causal relationship has not been established, reversible agranulocytosis (granulocytes ≤500/mm³) has been reported rarely.
Central nervous system: Because the eighth cranial nerve impairment such as dizziness, tinnitus, hearing loss, etc, may occur, close monitoring is required including testing hearing activity. As a rule, this drug should not be administered to patients with these symptoms, but if absolutely necessary, drug should be used with caution. Hearing loss associated with the drug has been reported in patients who had kidney dysfunction or a preexisting hearing loss or were receiving concomitant treatment with an ototoxic drug.
Liver: Because increased bilirubin, AST, ALT and ALP, rarely increased LDH, γ-GTP and LAP may occur, patients should be observed closely including regular monitoring. If any adverse reaction occurs, appropriate measure should be taken including discontinuation of administration.
Kidney: Because renal impairment such as increase BUN and creatinine may occur, patients should be observed closely including regular monitoring. As a rule, the drug should not be administered to patients with these adverse reactions, but if absolutely necessary, the drug should be used with caution.
Interstitial nephritis have been reported rarely in patients who were given aminoglycoside antibiotics or who had preexisting kidney dysfunction. When the drug was discontinued, azotemia resolved.
Skin: Exfoliative dermatitis, bullous dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis may occur.
Hypersensitivity reactions: When rash, erythema, flushing, hypotension, wheezing, dyspnea, urticarial and pruritus occurs, appropriate measure should be taken. Rapid infusion may also cause red-man's syndrome (erythema, bleeding of face, neck and upper body), pain of chest and abdomen and muscle spasm. These reactions usually resolve within 20 minutes but may persist for several hours. In animal studies where overdose of this drug was administered rapidly with high concentration, hypotension and bradycardia occurred. These adverse reactions rarely occur when the drug is slowly administered over a period not less than 60 minutes, and there was no injection related adverse reactions when this drug was administered to healthy human with a rate of not more than 10 mg/minute.
Others: Occasionally fever, angialgia, phlebitis, rarely, nausea, chills and vasculitis may occur, pseudomembranous colitis by Clostridium difficile also has been reported in patients who had administered the drug intravenously.